Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: A randomized, double-blind, placebo-controlled trial

Nakamura, T.; Mizutani, Jun; Ohki, Kohji; Yamada, Kazuhisa; Yamamoto, Naoyuki; Takeshi, Masahiko; Takazawa, Kenji

doi:10.1016/j.atherosclerosis.2011.06.007

Cited by 66 publications

(46 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, significant reductions in BP (either SBP or both SBP and DBP) were reported in the earlier studies of Jauhiainen et al (51) , Cicero et al (55) , Yoshizawa et al (48,49) , Nakamura et al (54) and Turpeinen et al (52,53) after feeding LTP, and intact whey and casein proteins (35) . However, in a number of these studies (48,49,55) , the significant results were expressed relative to baseline only.…”

Section: á a Fekete Et Almentioning

confidence: 76%

The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies

2013

View full text Add to dashboard Cite

CVD are the leading cause of death worldwide. Hypertension, a major controllable risk factor of CVD, is intimately associated with vascular dysfunction, a defect which is also now recognised to be a major, modifiable risk factor for the development of CVD. The purpose of the present review was to critically evaluate the evidence for the effects of milk proteins and their associated peptides on blood pressure (BP) and vascular dysfunction. After a detailed literature search, the number of human trials evaluating the antihypertensive effects of caseinderived peptides (excluding isoleucine-proline-proline and valine-proline-proline) was found to be limited; the studies were preliminary with substantial methodological limitations. Likewise, the data from human trials that examined the effects of whey protein and peptides were also scarce and inconsistent. To date, only one study has conducted a comparative investigation on the relative effects of the two main intact milk proteins on BP and vascular function. While both milk proteins were shown to reduce BP, only whey protein improved measures of arterial stiffness. In contrast, a growing number of human trials have produced evidence to support beneficial effects of both milk proteins and peptides on vascular health. However, comparison of the relative outcomes from these trials is difficult owing to variation in the forms of assessment and measures of vascular function. In conclusion, there is an accumulating body of evidence to support positive effects of milk proteins in improving and/or maintaining cardiovascular health. However, the variable quality of the studies that produced this evidence, and the lack of robust, randomised controlled intervention trials, undermines the formulation of firm conclusions on the potential benefits of milk proteins and peptides on vascular health.

show abstract

Section: á a Fekete Et Almentioning

confidence: 76%

The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies

2013

View full text Add to dashboard Cite

show abstract

“…All statistical tests were performed two-sided at 5 % level of significance using SPSS 20.0 for Mac OS X (SPSS Inc.). It was calculated that a sample size of twenty-eight subjects per treatment group (1, 2 and 5 g NWT-03) was needed to show an effect size of 7 mmHg in daytime SBP with a power of 80 % with an SD of the response of 9 mmHg (12,13) and an α of 0·05 (two-tailed).…”

Section: Statisticsmentioning

confidence: 99%

Effects of NWT-03, an egg-protein hydrolysate, on blood pressure in normotensive, high-normotensive and mild-hypertensive men and women: a dose-finding study

Severins

Morrison²,

Mensink

2017

Br J Nutr

View full text Add to dashboard Cite

Angiotensin-converting enzyme (ACE) inhibitors are important agents in blood pressure (BP) management. It was recently shown that the egg-protein hydrolysate NWT-03 inhibited ACE in Zucker diabetic fatty rats. We therefore designed a dose-finding study to assess the effects of 1, 2 and 5 g NWT-03 on daytime, 36-h, and night-time systolic and diastolic BP (SBP and DBP) in ninety-two generally healthy subjects with normal BP (n 29), high-normal BP (n 34) or mild hypertension (n 29). The study had a cross-over design with six treatment arms (1 g NWT-03 or placebo in period 1 and placebo or 1 g NWT-03 in period 2, 2 g NTW-03 or placebo in period 1 and placebo or 2 g NWT-03 in period 2, or 5 g NTW-03 or placebo in period 1 and placebo or 5 g NTW-03 in period 2). A comparable number of subjects from each BP class were included in each study arm. Duration of both treatments in each arm was 7 d, separated by 5-d wash-out periods. BP was measured with an ambulatory BP monitor before and after the treatments. In mild-hypertensive subjects, 2 g NWT-03 significantly decreased daytime SBP (7·9 mmHg; P = 0·006), daytime DBP (4·2 mmHg; P = 0·009), 36-h SBP (6·9 mmHg; P = 0·015) and 36-h DBP (3·5 mmHg; P = 0·035) compared with placebo subjects. In addition, in mild-hypertensive subjects, 5 g NWT-03 significantly decreased night-time SBP (14·8 mmHg; P = 0·008) and night-time DBP (8·4 mmHg; P = 0·020) compared with that in placebo subjects. To conclude, we found that 2 g NWT-03 lowered daytime and 36-h BP in subjects with mild hypertension, and 5 g NWT-03 lowered night-time BP in subjects with mild hypertension. As no doseresponse relationship was evident, these results should be interpreted with care, and additional studies are needed.

show abstract

“…In the framework of further assessment, two additional meta-analyses (Aubin, 2011, unpublished;Cicero et al, 2011) and six RCTs (Cicero et al, 2010;Ishida et al, 2007;Nakamura et al, 2011;Turpeinen et al, 2009;Usinger et al, 2010a;Yoshizawa et al, 2010) were provided as pertinent to the claim.…”

Section: Scientific Substantiation Of the Claimed Effect (Id 661 183mentioning

confidence: 99%

“…However, the Panel considers that these six studies have methodological weaknesses, which limit the interpretation of the results. Nakamura et al (2011) performed another randomised, double-blind, placebo-controlled parallel study which enrolled 70 hypertensive subjects without treatment for hypertension. After an eight-week screening period, subjects were randomised to receive tablets containing 3.4 mg per day IPP and VPP or placebo for eight weeks.…”

Section: Scientific Substantiation Of the Claimed Effect (Id 661 183mentioning

confidence: 99%

Scientific Opinion on the substantiation of health claims related to isoleucine‐proline‐proline (IPP) and valine‐proline‐proline (VPP) and maintenance of normal blood pressure (ID 661, 1831, 1832, 2891, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Products¹

2012

EFS2

View full text Add to dashboard Cite

Following a request from the European Commission, pursuant to Article 13.1 of Regulation (EC) No 1924No /2006, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a health claim related to isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) and maintenance of normal blood pressure. The food constituent that is the subject of the claim, the tripeptides isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), is sufficiently characterised. The claimed effect, maintenance of normal blood pressure, is a beneficial physiological effect. The proposed target population is the general population. In weighing the evidence, the Panel took into account that 15 of the human intervention studies provided, of which seven were adequately powered to detect small between-group differences in systolic blood pressure, did not observe an effect of IPP and VPP on systolic blood pressure or diastolic blood pressure; that interpretation of the results from nine out of the ten studies which reported an effect of IPP and VPP on office systolic blood pressure was limited by methodological weaknesses; that the animal and in vitro/ex vivo studies did not provide additional information on the effect of IPP and VPP on blood pressure in humans; and that there is no convincing evidence for a mechanism by which IPP and VPP could exert the claimed effect in humans at the proposed dose. On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of IPP and VPP and maintenance of normal blood pressure. © European Food Safety Authority, 2012 KEY WORDSIsoleucine-proline-proline, IPP, valine-proline-proline, VPP, blood pressure, health claims. Isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) and maintenance of normal blood pressure (further assessment) 2 EFSA Journal 2012;10(6):2715 SUMMARYFollowing a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924No /2006. The Commission has agreed with EU Member States that a certain number of Article 13 health claims would be eligible for further assessment by EFSA in order to be able to take a final decision on whether or not to include these claims in the list of permitted health claims. This opinion addresses the scientific substantiation of health claims in relation to the tripeptides isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) and maintenance of normal blood pressure. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims, references that EFSA has received from Member States or directly from stakeholders and the additional information provided by the competent Authority of Germany for further assessment of this claim.The food constituent that is the subject of th...

show abstract

Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: A randomized, double-blind, placebo-controlled trial

Cited by 66 publications

References 20 publications

The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies

The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies

Effects of NWT-03, an egg-protein hydrolysate, on blood pressure in normotensive, high-normotensive and mild-hypertensive men and women: a dose-finding study

Scientific Opinion on the substantiation of health claims related to isoleucine‐proline‐proline (IPP) and valine‐proline‐proline (VPP) and maintenance of normal blood pressure (ID 661, 1831, 1832, 2891, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Contact Info

Product

Resources

About